Understanding how immune cells affect kidney disease in Tuberous Sclerosis Complex
Official title: Mechanisms of immunosuppression in the development and progression of renal disease in Tuberous Sclerosis Complex
Funded at Brigham and Women's Hospital · NIH-11101408 · Data updated 2026-11-12
This study is looking at how certain immune cells might be affecting kidney problems in people with Tuberous Sclerosis Complex, and it aims to find new ways to help improve kidney health for those living with this condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Brigham and Women's Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | April 5, 2023 |
| Project end | March 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $523,592 |
| NIH project number | 5R01DK133243-03 |
| Project ID | NIH-11101408 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals diagnosed with Tuberous Sclerosis Complex who are experiencing renal disease, such as angiomyolipomas or cysts.
✕Less likely to help
Patients without Tuberous Sclerosis Complex or those not experiencing renal complications may not benefit from this research.
What this research studies
This research investigates the role of specific immune cells, particularly immunosuppressive macrophages, in the development and progression of kidney disease associated with Tuberous Sclerosis Complex (TSC). The study aims to uncover how these immune cells and a molecule called B7-H3 contribute to kidney problems in TSC patients. By examining tissue samples and conducting experiments, researchers hope to identify potential therapeutic targets that could improve kidney health in affected individuals. The ultimate goal is to develop new treatment strategies that could enhance immune function and reduce kidney disease severity.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that improve kidney health and overall outcomes for patients with Tuberous Sclerosis Complex.
How similar studies have gone: Previous research has shown promising results in targeting immune mechanisms in other diseases, suggesting potential for success in this novel approach.
Where this research is happening
-
Brigham and Women's Hospital
Boston, United States Active
Researchers
- Principal investigator: Henske, Elizabeth P — Brigham and Women's Hospital
- Study coordinator: Henske, Elizabeth P
Related research
Other NIH-funded projects on the same topics.
-
Immune causes of kidney disease in tuberous sclerosis
The team is looking at whether immune cells and a protein called B7-H3 help kidney cysts and growths in people with tuberous sclerosis complex.
-
Vascular signals from brain blood vessels influence immune-suppressing cells in glioblastoma
This grant explores how blood vessel cells in glioblastoma shape immune cells to help the tumor grow, with the aim of making immunotherapies work better for patients.
-
Vascularized niche with local immune protection to transplant insulin-producing cells for Type 1 diabetes
A new approach aims to transplant insulin-producing cells inside a vascularized pocket with local drug delivery to keep them alive and functioning without full-body immune suppression.
-
VIP Interneurons and Brain Circuits in Tuberous Sclerosis
A study to understand how loss of a brain gene (Tsc1) affects VIP interneurons and the frontal brain region in people and models with Tuberous Sclerosis Complex.
-
AHR-driven immunosuppression in glioblastoma and new therapeutic targets
A personalized cancer study aims to understand why glioblastoma suppresses the immune system and to find ways to boost anti-tumor immunity in patients with this brain tumor.
-
Fibroblast-made GABA fuels PDAC immune suppression
In people with pancreatic cancer, this study explores how a specific cell type in the tumor environment uses a brain-like chemical (GABA) to dampen immune attack against the cancer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.